Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically interesting drugs that targets XPO1 in clinical development. In this review, we summarized the most relevant preclinical and clinical results achieved for non-solid tumors, sarcomas, and other kind of solid tumors.

中文翻译：

---

Selinexor 和选择性抑制核输出：治疗肉瘤和其他实体和非实体肿瘤的新视角

已发现核细胞质转运在许多类型的癌症中失调，通常被描述为不良预后因素。具体而言，Exportin-1 (XPO1) 在许多肿瘤中被发现过度表达，并已成为分子肿瘤学和治疗学开发中的一个有吸引力的目标。选择性核输出抑制剂 Selinexor 是临床开发中靶向 XPO1 的最具科学意义的药物之一。在这篇综述中，我们总结了非实体瘤、肉瘤和其他类型实体瘤取得的最相关的临床前和临床结果。